Drugs / F-18 FDG
F-18 FDG
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07825818 | Sep 2026 → Dec 2032 expected | alcohol-related disorders | Rajesh Narendran | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01609335 | Jul 2012 → Aug 2013 | Alzheimer disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01623284 | Mar 2010 → Jan 2015 | aphasia, apraxia, semantic dementia | Mayo Clinic | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05009979 | Jan 2023 → Nov 2024 | hepatocellular carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03125629 | May 2014 → Nov 2016 | — | Stanford University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07087106 | May 2025 → Dec 2027 expected | multiple sclerosis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04804371 | Mar 2021 → Feb 2027 expected | neuroendocrine neoplasm | University Health Network, Toronto | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 FDG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01623284 ↗ |
| Known as | 18-fluorodeoxyglucose | “using the radiolabeled glucose analogue 18-fluorodeoxyglucose” NCT07087106 ↗ |
| Known as | 18F-FDG | “18F-FDG tracer (5 MBq/kg body weight of FDG; up to 550 MBq) will be injected into the intravenous” NCT04804371 ↗ |
| Known as | 18F-fludeoxyglucose | “Patients receive standard of care 18F-fludeoxyglucose (FDG) or Ga68-DOTA-TATE intravenously (IV).” NCT03125629 ↗ |
| Known as | FDG | “Patients receive standard of care 18F-fludeoxyglucose (FDG) or Ga68-DOTA-TATE intravenously (IV).” NCT03125629 ↗ |
| Modality | Diagnostic / imaging agent | “F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.” NCT01609335 ↗ |
| Route | Intravenous | “One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).” NCT01623284 ↗ |